Welcome to our dedicated page for Morphic Holding news (Ticker: MORF), a resource for investors and traders seeking the latest updates and insights on Morphic Holding stock.
Morphic Holding (MORF) delivers innovative oral integrin therapies targeting chronic diseases through advanced small molecule research. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access verified information about MORF-057 clinical trials, partnership announcements, and financial disclosures. Our curated collection ensures you stay informed about Morphic's progress in transforming autoimmune and inflammatory disease treatments through its proprietary MInT technology platform.
Discover press releases covering key areas: clinical trial results, research collaborations, regulatory filings, and financial performance. Bookmark this page for real-time updates on Morphic's pipeline advancements and scientific breakthroughs in oral integrin therapeutics.
Morphic Therapeutic (MORF) reported positive Phase 1 data for MORF-057, a targeted oral integrin therapy for ulcerative colitis. The Phase 2a trial is anticipated to start in Q1 2022, with a Phase 2b trial commencing mid-year. The company also showcased promising preclinical results from its αvβ8 program, demonstrating anti-tumor activity. Morphic ended 2021 with $408 million in cash, sufficient to cover operations through 2024. However, the net loss for 2021 increased to $95.5 million from $45 million in 2020, alongside a revenue drop from $44.9 million to $19.8 million.
Morphic Therapeutic (Nasdaq: MORF) announced new preclinical data at the ECCO Congress supporting its ongoing MORF-057 program for inflammatory bowel disease (IBD). The studies characterized α4β7 expression in immune cells and the dose-dependent effect of MORF-057 in nonhuman primates, aligning with human clinical data. The findings enhance the understanding of α4β7 inhibitor pharmacology, boosting confidence as the company advances to Phase 2 studies. The presentation included data from five studies demonstrating receptor saturation and biomarker responses.
Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, M.D., will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. The presentation will focus on the company's advancements in developing oral integrin therapies targeting chronic diseases. A live webcast can be accessed via the investor section of Morphic's website, with a replay available afterward. Morphic is collaborating with major firms to enhance its therapies using its proprietary MInT technology platform.
Morphic Therapeutic (Nasdaq: MORF), a biotechnology firm specializing in oral integrin therapies for chronic diseases, has announced its participation in upcoming investor conferences. Dr. Bruce N. Rogers will present at the Jefferies London Healthcare Conference on November 17 at 1:40 PM GMT. Additionally, the Morphic management team will provide updates at the Evercore ISI HealthCONx Conference on December 2 at 1:25 PM ET. Both events will be accessible via live webcast on Morphic's investor website, with replays available afterward.
Morphic Therapeutic (Nasdaq: MORF) presented new data demonstrating that αvβ8 integrin inhibition significantly enhances anti-tumor responses in advanced colon cancer models resistant to existing therapies. The research, showcased at the SITC 2021 Annual Meeting, indicates that the combination of αvβ8 inhibitors with radioimmunotherapy (RIT) led to increased tumor regression (P=0.0067) and survival rates (P<0.0001). Eight out of ten subjects receiving the combination therapy responded completely, compared to three out of ten with RIT alone, highlighting the potential for αvβ8 inhibitors in combination immunotherapy.
Morphic Therapeutic (Nasdaq: MORF) reported positive phase 1 data for MORF-057, an oral integrin therapy for ulcerative colitis, with no safety signals identified. The company plans to start a phase 2a trial in 1Q22, assessing 30-35 patients. Financially, Morphic experienced a net loss of $25 million or $0.69 per share for Q3 2021, with revenue dropping to $3.1 million due to a prior year $20 million payment from AbbVie. R&D expenses rose to $21 million, while general and administrative costs increased to $7.3 million. However, Morphic's cash position remains strong at $427.6 million, sufficient to fund operations until late 2024.
Morphic Therapeutic (Nasdaq: MORF) announced participation in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on October 19, 2021, at 3:15 p.m. ET. The event will showcase Morphic's leadership team discussing advancements in oral integrin therapies for serious chronic diseases, including autoimmune and cardiovascular conditions. A live webcast will be available on the company’s investor website, with an archived replay accessible post-event. Morphic is advancing its pipeline through collaborations with AbbVie, Janssen, and Schrödinger.
Morphic Therapeutic (Nasdaq: MORF) will participate in two major investor conferences. CEO Dr. Praveen Tipirneni and COO Marc Schegerin will hold a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 12:30 p.m. ET. They will also host virtual meetings during the Citi 16th Annual BioPharma Virtual Conference from September 8 to 10. A live webcast of the fireside chat will be available on Morphic’s website, with an archived replay to follow.
Morphic Therapeutic (Nasdaq: MORF) announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda, currently Chief Development Officer at Loxo Oncology, brings over 20 years of biopharma experience, particularly in drug development. With a Ph.D. in biochemistry, her expertise will bolster Morphic's strategy as it advances its oral integrin portfolio, especially moving into mid-stage clinical trials for MORF-057 in inflammatory bowel disease (IBD). The company aims to leverage its proprietary MInT technology platform to address serious chronic diseases.
Morphic Therapeutic (NASDAQ: MORF) reported successful Phase 1 results for MORF-057, indicating high tolerability and exceeding pharmacokinetic targets. A Phase 2a trial for moderate to severe ulcerative colitis is set to begin in 1Q22. The company presented promising data at the AACR Annual Meeting regarding its αvβ8 immuno-oncology program. Financially, the company reported a net loss of $27.8 million for Q2 2021, with revenues down to $3.8 million. Morphic’s cash position stands at $431.6 million, projected to fund operations through 2024.
